Mesocarb

Mesocarb
Clinical data
Trade names	Sidnocarb, Sydnocarb, Synocarb
Other names	Fensidnimine; Pharmaneocarb; Sydnocarbum; MLR-1017; N-Phenylcarbamoyl-3-(β-phenylisopropyl)sydnonimine; 3-(β-Phenylisopropyl)-N-phenylcarbamoylsydnonimine
Routes of; administration	Oral
Drug class	Atypical dopamine reuptake inhibitor
ATC code	None;
Legal status
Legal status	BR: Class B1 (Psychoactive drugs); CA: Schedule III; DE: Anlage II (Authorized trade only, not prescriptible); UK: Class C; US: Schedule I;
Pharmacokinetic data
Metabolism	Hepatic
Excretion	Renal
Identifiers
	IUPAC name 5-(Phenylcarbamoylimino)-3-(1-phenylpropan-2-yl)-5H-1,2,3-oxadiazol-3-ium-2-ide;
CAS Number	34262-84-5 ;
PubChem CID	9551611;
PubChem SID	497621129;
ChemSpider	16736988 ;
UNII	UMT8MP2NDU;
KEGG	D12716 ;
CompTox Dashboard (EPA)	DTXSID10900961 ;
Chemical and physical data
Formula	C18H18N4O2
Molar mass	322.368 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(\N=C1/C=[N+](\[N-]O1)C(C)Cc2ccccc2)Nc3ccccc3;
	InChI InChI=1S/C18H18N4O2/c1-14(12-15-8-4-2-5-9-15)22-13-17(24-21-22)20-18(23)19-16-10-6-3-7-11-16/h2-11,13-14H,12H2,1H3,(H,19,23)/b20-17+ ; Key:DMHQLXUFCQSQQQ-LVZFUZTISA-N ;
	(verify)

Mesocarb, sold under the brand name Sidnocarb or Sydnocarb and known by the developmental code name MLR-1017, is a psychostimulant medication which has been used in the treatment of psychiatric disorders and for a number of other indications in the Soviet Union and Russia. It is currently under development for the treatment of Parkinson's disease and sleep disorders. It is taken by mouth.

The drug is a selective dopamine reuptake inhibitor (DRI). It is an unusual and unique DRI, acting as a negative allosteric modulator and non-competitive inhibitor of the dopamine transporter (DAT). Chemically, mesocarb contains amphetamine within its structure but has been modified and extended at the amine with a sydnone imine-containing moiety.

Mesocarb was first described by 1971. It was used as a pharmaceutical drug until 2008. In 2021, its nature as a DAT allosteric modulator was reported. As of February 2023, mesocarb was in phase 1 clinical trials for Parkinson's disease. The active enantiomer, armesocarb, is also being developed.